scholarly journals Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021

2022 ◽  
Vol 27 (1) ◽  
Author(s):  
Marta Grgič Vitek ◽  
Irena Klavs ◽  
Veronika Učakar ◽  
Mojca Serdt ◽  
Maja Mrzel ◽  
...  

We estimated vaccine effectiveness (VE) against severe COVID-19 during October 2021, using Slovenian surveillance data. For people fully vaccinated with any vaccine in age groups 18–49, 50–64, ≥ 65 years, VE was 86% (95% CI: 79–90), 89% (85–91), and 77% (74–81). Among ≥ 65 year-olds fully vaccinated with mRNA vaccines, VE decreased from 93% (95% CI: 88–96) in those vaccinated ≤ 3 months ago to 43% (95% CI: 30–54) in those vaccinated ≥ 6 months ago, suggesting the need for early boosters.

2021 ◽  
Vol 11 (4) ◽  
pp. 1696
Author(s):  
Mario Giosuè Balzanelli ◽  
Pietro Distratis ◽  
Orazio Catucci ◽  
Angelo Cefalo ◽  
Rita Lazzaro ◽  
...  

Due to the promising effects of mesenchymal stem cells (MSCs) in the treatment of various diseases, this commentary aimed to focus on the auxiliary role of MSCs to reduce inflammatory processes of acute respiratory infections caused by the 2019 novel coronavirus (COVID-19). Since early in 2020, COVID-19, a consequence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly affected millions of people world-wide. The SARS-CoV-2 infection in children appears to be an unusual event. Despite the high number of affected adult and elderly, children and adolescents remained low in amounts, and marginally touched. Based on the promising role of cell therapy and regenerative medicine approaches in the treatment of several life-threatening diseases, it seems that applying MSCs cell-based approaches can also be a hopeful strategy for improving subjects with severe acute respiratory infections caused by COVID-19.


2015 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
Jorge Cortes ◽  
Liliana Diaz ◽  
Sandra Gomez ◽  
Alejandra Guarnizo ◽  
Tatiana Olarte ◽  
...  

2011 ◽  
Vol 65 (Suppl 1) ◽  
pp. A96-A96
Author(s):  
A. Cabello ◽  
M. V. Horoch ◽  
L. Bobadilla ◽  
C. Vazquez ◽  
M. Samudio ◽  
...  

2018 ◽  
Vol 1 (6) ◽  
pp. e47 ◽  
Author(s):  
Luiz Gustavo dos Anjos Borges ◽  
Adriana Giongo ◽  
Leandro de Mattos Pereira ◽  
Fernanda J. Trindade ◽  
Tatiana Schäffer Gregianini ◽  
...  

2019 ◽  
Vol 24 (20) ◽  
Author(s):  
Laura M Vos ◽  
Anne C Teirlinck ◽  
José E Lozano ◽  
Tomás Vega ◽  
Gé A Donker ◽  
...  

Background To control respiratory syncytial virus (RSV), which causes acute respiratory infections, data and methods to assess its epidemiology are important. Aim We sought to describe RSV seasonality, affected age groups and RSV-type distribution over 12 consecutive seasons in the Netherlands, as well as to validate the moving epidemic method (MEM) for monitoring RSV epidemics. Methods We used 2005−17 laboratory surveillance data and sentinel data. For RSV seasonality evaluation, epidemic thresholds (i) at 1.2% of the cumulative number of RSV-positive patients per season and (ii) at 20 detections per week (for laboratory data) were employed. We also assessed MEM thresholds. Results In laboratory data RSV was reported 25,491 times (no denominator). In sentinel data 5.6% (767/13,577) of specimens tested RSV positive. Over 12 seasons, sentinel data showed percentage increases of RSV positive samples. The average epidemic length was 18.0 weeks (95% confidence intervals (CI):  16.3–19.7) and 16.5 weeks (95% CI: 14.0–18.0) for laboratory and sentinel data, respectively. Epidemics started on average in week 46 (95% CI: 45–48) and 47 (95% CI:  46–49), respectively. The peak was on average in the first week of January in both datasets. MEM showed similar results to the other methods. RSV incidence was highest in youngest (0–1 and >1–2 years) and oldest (>65–75 and > 75 years) age groups, with age distribution remaining stable over time. RSV-type dominance alternated every one or two seasons. Conclusions Our findings provide baseline information for immunisation advisory groups. The possibility of employing MEM to monitor RSV epidemics allows prospective, nearly real-time use of surveillance data.


2021 ◽  
Vol 27 (1) ◽  
pp. 324-326
Author(s):  
Md R. Rahaman ◽  
Karen A. Alroy ◽  
Chris A. Van Beneden ◽  
Michael S. Friedman ◽  
Erin D. Kennedy ◽  
...  

2020 ◽  
Vol 26 (1) ◽  
pp. 148-150 ◽  
Author(s):  
Susana Monge ◽  
Janneke Duijster ◽  
Geert Jan Kommer ◽  
Jan van de Kassteele ◽  
Gé A. Donker ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document